Sands Capital Management
SPRB

Sands Capital Management’s Spruce Biosciences SPRB Stock Holding History

Sands Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,493
Closed -$8.82M – 79
2021
Q2 		$8.82M Hold
10,493
– – 0.02% 76
2021
Q1 		$13.1M Hold
10,493
– – 0.03% 72
2020
Q4 		$19.1M Buy
+10,493
New +$17.4M 0.04% 74

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Sands Capital Management's SPRB Position: Q3 2021 in Review

Sands Capital Management sold out of Spruce Biosciences (SPRB) in Q3 2021, closing a stake of 10,493 shares — an estimated $8.82M sold.

Sands Capital Management first reported a position in SPRB in Q4 2020 and held it in 3 quarters. The position peaked at $19.1M in Q4 2020. 43 funds tracked by Wall St. Rank hold SPRB as of Q3 2021.

  • Sands Capital Management reported no remaining Spruce Biosciences position as of Q3 2021 after selling out during the quarter.
  • Sands Capital Management sold 10,493 Spruce Biosciences shares in Q3 2021, an estimated $8.82M.
  • Sands Capital Management first reported a position in Spruce Biosciences in Q4 2020 and held it in 3 quarters.
  • Sands Capital Management's Spruce Biosciences position peaked at $19.1M in Q4 2020.
  • 43 funds tracked by Wall St. Rank held Spruce Biosciences as of Q3 2021.

Based on Sands Capital Management's 13F filing for Q3 2021, filed 3 Nov 2021.